Meritage Pharma begins OBS phase II clinical trial
EoE is a chronic disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation. The 16-week study will enroll about 100 patients at multiple US clinical centers
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.